TuHURA Biosciences HURA 深 沪
等待开盘 10-09 09:30:00 美东时间
1.93
-0.050
-2.53%
华盛通- 最 高1.97
- 今 开1.95
- 成交量 31.62万股
- 最 低 1.89
- 昨 收 1.98
- 总市值 1.23亿
- 52周最高 3.43
- 市盈率 静 --
- 换手率 0.50%
- 52周最低 0.41
- 委 比 34.32%
- 总股本 6372.66万
- 历史最高 190225.00
- 量 比 1.30
- 振 幅 4.04%
- 历史最低 0.41
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多TuHURA Biosciences Receives U.S. Patent For Administration Of DOR Antagonists
TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,734,168 entitled, “Delt...
10-05 19:48
TuHURA Biosciences Draws Additional Funds From Credit Facility
TuHURA Biosciences ( ($HURA) ) just unveiled an announcement. TuHURA Bioscience...
09-25 05:30
TuHURA Biosciences Adopts 2026 Inducement Equity Plan
The latest update is out from TuHURA Biosciences ( ($HURA) ). On September 10, ...
09-17 05:30
TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome res...
09-08 19:45
TuHURA Biosciences draws additional funds from credit facility
TuHURA Biosciences ( ($HURA) ) has shared an update. TuHURA Biosciences, Inc. p...
09-05 05:51
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Parabilis Medicines announced the appointment of Craig L. Tendler, M.D., to its Board of Directors. Dr. Tendler, a seasoned oncology expert with over 30 years of experience at Johnson & Johnson, will also continue his role as a scientific advisor. His extensive background in clinical development and regulatory approvals is expected to significantly benefit Parabilis as it advances its lead drug, zolucatetide, and expands its pipeline of innovativ...
08-25 11:00
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Citizens Reiterates Market Outperform on TuHURA Biosciences, Maintains $9 Price Target
Citizens analyst Silvan Turkcan reiterates TuHURA Biosciences (NASDAQ:HURA) with a Market Outperform and maintains $9 price target.
08-18 20:19
TuHURA Biosciences Q2 EPS $(0.14) Beats $(0.15) Estimate
TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 33.33 percent increase over losses of $(0.21) per share from the same period last year.
08-14 20:04
TuHURA Biosciences Submits Investigational New Drug Application With FDA For Trial Of Its TBS-2025 VISTA Antibody To Treat Molecularly Defined Subsets Of Acute Myeloid Leukemia
TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administrati...
06-15 19:52
